Abstract
Introduction
Non-randomized trials suggest that metformin may reduce TSH levels through unknown mechanisms.
Objective
To evaluate whether metformin can reduce TSH levels in subjects with subclinical hypothyroidism.
Patients and methods
This is a randomized, double-blind, placebo controlled clinical trial with 3 months duration that enrolled 48 individuals, between 18 and 65 years, with subclinical hypothyroidism. The patients were randomized to the use of metformin 850 mg or placebo twice a day for 3 months. The primary outcome was the absolute decrease in TSH levels. Secondary outcomes were changes in the clinical and laboratory assessment, as well as in blood pressure assessed by ambulatory blood pressure monitoring.
Results
After 3 months, 93.75% of participants completed the follow-up. The post treatment value of TSH in the metformin and placebo groups were 6.48 ± 3.11 and 7.02 ± 3.28 mIU/L, respectively (p = 0.57). Patients who achieved status of euthyroidism in the metformin and placebo groups were 21.7 and 18.2%, respectively (p = 0.76). There was no significant reduction of TSH within the groups [delta for TSH of 0.63 ± 0.56 (p = 0.28) and 0.54 ± 0.60 mIU/L (p = 0.38), in metformin and placebo groups, respectively]. There was a small increase in HDL cholesterol (1.62 ± 0.45 vs. 1.34 ± 0.39 mmol/L, p = 0.03) favoring the metformin group.
Conclusion
Since the sample size was small, the study was inconclusive and the results should be considered preliminary data of a study that needs to enroll 1626 patients to show a 0.5 mIU/L difference in TSH between the groups, with 90% power.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
B. Biondi, D.S. Cooper, The clinical significance of subclinical thyroid dysfunction. Endocr. Rev. 29(1), 76–131 (2008)
J.G. Hollowell, N.W. Staehling, W.D. Flanders et al., Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocrinol. Metab. 87(2), 489–499 (2002)
J.A. Sgarbi, P.F. Teixeira, L.M. Maciel et al., The Brazilian consensus for the clinical approach and treatment of subclinical hypothyroidism in adults: recommendations of the thyroid Department of the Brazilian Society of Endocrinology and Metabolism. Arq. Bras. Endocrinol. Metabol. 57(3), 166–183 (2013)
N. Rodondi, W.P. den Elzen, D.C. Bauer et al., Subclinical hypothyroidism and the risk of coronary heart disease and mortality. J. Am. Med. Assoc. 304(12), 1365–1374 (2010)
V. Kotsis, M. Alevizaki, S. Stabouli et al., Hypertension and hypothyroidism: results from an ambulatory blood pressure monitoring study. J. Hypertens. 25(5), 993–999 (2007)
H.C. Villar, H. Saconato, O. Valente et al., Thyroid hormone replacement for subclinical hypothyroidism. Cochrane Database Syst. Rev. 18(3), CD003419 (2007).
R. Lupoli, A. Di Minno, A. Tortora et al., Effects of treatment with metformin on TSH levels: a meta-analysis of literature studies. J. Clin. Endocrinol. Metab. 99(1), E143–E148 (2014)
M.L. Isidro, M.A. Penín, R. Nemiña et al., Metformin reduces thyrotropin levels in obese, diabetic women with primary hypothyroidism on thyroxine replacement therapy. Endocrine 32(1), 79–82 (2007)
C. Cappelli, M. Rotondi, I. Pirola et al., TSH-lowering effect of metformin in type 2 diabetic patients: differences between euthyroid, untreated hypothyroid, and euthyroid on L-T4 therapy patients. Diabetes Care 32(9), 1589–1590 (2009)
R.A. Vigersky, A. Filmore-Nassar, A.R. Glass, Thyrotropin suppression by metformin. J. Clin. Endocrinol. Metab. 91(1), 225–227 (2006)
S. Morteza Taghavi, H. Rokni, S. Fatemi, Metformin decreases thyrotropin in overweight women with polycystic ovarian syndrome and hypothyroidism. Diabetes Vasc. Dis. Res. 8(1), 47–48 (2011)
J. Meyerovitch, P. Rotman-Pikielny, M. Sherf et al., Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians. Arch. Intern. Med. 167(14), 1533–1538 (2007)
M. Karimifar, A. Aminorroaya, M. Amini et al., Effect of metformin on thyroid stimulating hormone and thyroid volume in patients with prediabetes: a randomized placebo-controlled clinical trial. J. Res. Med. Sci. 19(11), 1019–1026 (2014)
R. Krysiak, W. Szkróbka, B. Okopień, Sex-dependent effect of metformin on hypothalamic-pituitary-thyroid axis activity in patients with subclinical hypothyroidism. Pharmacol. Rep. 68(6), 1115–1119 (2016)
E. Selvin, S. Bolen, H.C. Yeh et al., Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch. Intern. Med. 168(19), 2070–2080 (2008)
K. Landin-Wilhelmsen, Metformin and blood pressure. J. Clin. Pharm. Ther. 17(2), 75–79 (1992)
Acknowledgements
Fundo de Incentivo a Pesquisa e Eventos do Hospital de Clínicas de Porto Alegre (FIPE-HCPA) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Rights and permissions
About this article
Cite this article
Dornelles Severo, M., Stürmer Andrade, T., Correa Junior, V. et al. Metformin effect on TSH in subclinical hypothyroidism: randomized, double-blind, placebo-controlled clinical trial. Endocrine 59, 66–71 (2018). https://doi.org/10.1007/s12020-017-1462-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-017-1462-7